Format

Send to

Choose Destination
See comment in PubMed Commons below
Rev Gastroenterol Peru. 2014 Oct-Dec;34(4):315-20.

[Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events].

[Article in Spanish]

Author information

1
Hospital de Huamanga. Ayacucho, Perú.
2
Departamento del Aparato Digestivo. Hospital Edgardo Rebagliati. Lima, Perú.

Abstract

OBJECTIVES:

To establish the efficiency and adverse effects of the addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection.

MATERIAL AND METHODS:

Double blind controlled experimental trial. The study population consisted of 54 patients with Helicobacter pylori infection: 29 were allocated to the experimental group, who received the usual triple plus bismuth subsalicylate therapy, and 24 received the triple therapy plus placebo.

RESULTS:

The average age was 47+-14.9 years, 66.7% of the patients were women. Both groups underwent the breath test: it was negative in 89.7% of the patients from the experimental group and 80% of the patients from the placebo group (p=0.319). The adverse events of both groups were: diarrhea (10.3% in the experimental group vs 16% in the placebo group; p=0.537), dark feces (37.9% in the experimental group vs 0% in the placebo group; p=0.001), abdominal pain (20.7% in the experimental group vs 52% in the placebo group; p=0.016). Nausea only were present in 3% of the patients of placebo group p=0.055).

CONCLUSIONS:

The association of bismuth subsalicylate to the triple therapy scheme for the eradication of Helicobacter pylori was effective in 89.7% of patients, whereas 80% of efficiency in the experimental group.

PMID:
25594755
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center